Gsk Competitive Structure

701 Words3 Pages
Introduction As part of valuation and financial modelling course, we were required to realize the valuation of a company listed FTSE 350. I personally made the choice of a leading company in Pharmaceutical and Healthcare industry, GlaxoSmithKline (GSK). GSK is a British company born in 2000 with the merger of Glaxo Wellcome Plc and SmithKline Beecham Plc, it researches and develops pioneering products in three major areas: Pharmaceuticals, Vaccines and Consumer Healthcare. In 2014, GSK has been ranked 7th world largest Pharmaceutical firm in terms of revenue (1st in the UK) by GlobalData. Source: GlobalData I- Competitive structure of Pharmaceutical industry In order to analyse the competitive structure of Pharmaceutical industry, I will proceed to a Porter’s Five Forces analysis. Before starting Porter analysis, I’ll present to you some Key figures from Pharmaceutical Industry. The global market had a total revenue of 808.1bn in 2013 and is expected to exceed 1 trillion for 2014. The growth have been 4 % from 2009 and 2013 according to Market Line report. In terms of geography, Americas represent 43.8% of the total market, followed by Asia-Pacific and Europe (28.7% and 26.2% respectively). The average profitability in this industry is 19%, making it the most profitable industry among all sectors. Source: Pharmaceutical industry gets high on fat profits, bbc.com 1- The bargaining power of buyers The principal buyers in this industry are wholesalers, those who are responsible for distributing drugs among pharmacies and hospitals. Because Doctors’ prescriptions will depend on the medical situation of the patient, the later have small opportunity to choose between different drugs. This weakens buyer position. However, the intervention of government in pricing and the raising social considerations bring some balance to the existing relationship between buyers and
Open Document